Does Massachusetts Medicaid Cover Wegovy or Zepbound?
Massachusetts (MA) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does Massachusetts Medicaid cover weight-loss GLP-1s, has Massachusetts expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
Massachusetts Medicaid GLP-1 coverage: what the state's own documents say
MassHealth's own Drug List update excludes anti-obesity agents effective July 3, 2026 under 130 CMR 406.413(B)(7) (announced to plans and the press as July 1) and now covers Wegovy (injection and tablet) and Zepbound only for reducing cardiovascular events with established heart disease, MASH, and moderate-to-severe sleep apnea with obesity; members under 21 can still be reviewed for medical necessity under EPSDT.
Checked September 20, 2026 against: mhdl.pharmacy.services.conduent.com, mhdl.pharmacy.services.conduent.com, mass.gov.
Massachusetts state employee health plan: what the plan's own documents say
The Massachusetts Group Insurance Commission has not covered GLP-1s prescribed only for weight loss for non-Medicare members since July 1, 2026 (the Commission voted 10-7 on February 26, 2026); GLP-1s remain covered for diabetes, and a CVS Caremark prior authorization can still approve narrow non-weight-loss uses (cardiovascular disease with BMI 27 or higher, sleep apnea with BMI 30 or higher, MASH).
Checked September 20, 2026 against: mass.gov, nage.org.
Notable insurers active in Massachusetts (not independently verified): Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (Massachusetts is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the Massachusetts-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for Massachusetts residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Does Massachusetts Medicaid cover Wegovy or Zepbound for weight loss?
No - coverage ended July 3, 2026. MassHealth's own Drug List update excludes anti-obesity agents effective July 3, 2026 under 130 CMR 406.413(B)(7) (announced to plans and the press as July 1) and now covers Wegovy (injection and tablet) and Zepbound only for reducing cardiovascular events with established heart disease, MASH, and moderate-to-severe sleep apnea with obesity; members under 21 can still be reviewed for medical necessity under EPSDT. This was checked against Massachusetts's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has Massachusetts expanded Medicaid under the ACA?
Yes - Massachusetts has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the Massachusetts state employee health plan cover Wegovy or Zepbound?
No. The Massachusetts Group Insurance Commission has not covered GLP-1s prescribed only for weight loss for non-Medicare members since July 1, 2026 (the Commission voted 10-7 on February 26, 2026); GLP-1s remain covered for diabetes, and a CVS Caremark prior authorization can still approve narrow non-weight-loss uses (cardiovascular disease with BMI 27 or higher, sleep apnea with BMI 30 or higher, MASH). This was checked against Massachusetts's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.